Jessica A Walsh1, Marilyn T Wan1, Christine Willinger1, M Elaine Husni1, Jose U Scher1, Soumya M Reddy1, Alexis Ogdie1. 1. From the Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; University of Pennsylvania, Philadelphia, PA, USA; Cleveland Clinic, Cleveland, OH, USA; New York University School of Medicine, New York, NY, USA. Funding: This work was supported by NIH/NIAMS R01 AR072363. Dr. Walsh has received consulting fees or research grants from Novartis, AbbVie, Amgen, Lilly, and Pfizer Dr. Husni has received consulting fees, speaking fees, and/or honoraria from AbbVie, Janssen, Sanofi Genzyme/Regeneron, UCB, Novartis, and Lilly (less than $10,000 each) and is a coinventor on a patent for a psoriatic arthritis questionnaire (Psoriatic Arthritis Screening Evaluation), for which she receives royalties. Dr. Reddy has received consulting fees, speaking fees, and/or honoraria from Novartis, AbbVie, Amgen, UCB, and Pfizer (less than $10,000 each). Dr. Scher has received consulting fees from Janssen, UCB, BMS (less than $10,000 each), consulting fees from Novartis (more than $10,000) and consulting fees or research grants from Novartis to NYU Langone Health. Dr. Ogdie has received consulting fees, speaking fees, and/or honoraria from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Lilly, Novartis, Pfizer, and Takeda (less than $10,000 each). Grants from Novarits and Pfizer to the trustees of University of Pennsylvania. Royalties to husband from Novartis (greater than $10,000). Dr. Wan and Ms. Willinger have no relevant financial disclosures with respect to the work presented. Corresponding Author: Alexis Ogdie, Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; tel: 215-615-4375; fax: 215-662-4500; alexis.ogdie@uphs.upenn.edu.
Abstract
OBJECTIVE: To examine the construct validity of Routine Assessment of Patient Index Data (RAPID3) and Psoriatic Arthritis Impact of Disease (PSAID) in patients with psoriatic arthritis (PsA). In examining construct validity, we also addressed scores among subgroups with severe psoriasis, polyarticular disease, enthesitis and dactylitis and evaluated influences of sociodemographic factors and comorbidities (contextual factors) on these patient-reported outcomes (PROs). METHODS: Patients with PsA were enrolled in the Psoriatic Arthritis Research Consortium (PARC) between 2014-2016. PARC is a longitudinal observational cohort study conducted at four United States institutions. In this cross-sectional study, construct validity was assessed by examining Spearman's correlation coefficients for RAPID3 and PSAID with physician-reported disease activity measures and other PROs (e.g., Short Form 12 (SF12-PCS/-MCS), Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue). Contextual factors and disease subgroups were assessed in multivariable linear regression models with RAPID3 or PSAID12 as outcomes of interest and the hypothesized contextual factors as covariates. RESULTS: Among 401 patients enrolled in PARC, 347 completed RAPID3 or PSAID12. Of these, most were Caucasian females with a mean age of 51.74 (SD 14.02). RAPID3 and PSAID were highly correlated (r=0.90). These measures were also correlated with the SF12-PCS (r=-0.67) and FACIT-Fatigue (r=-0.77). Important contextual factors and disease subgroups included enthesitis, joint counts, education, insurance type, and depression. CONCLUSION: RAPID3 and PSAID12 have excellent construct validity in PsA and are strongly correlated despite differing items. Contextual factors (i.e., the presence of depression and obesity) should be considered when interpreting raw scores of the RAPID3 and PSAID12.
OBJECTIVE: To examine the construct validity of Routine Assessment of Patient Index Data (RAPID3) and Psoriatic Arthritis Impact of Disease (PSAID) in patients with psoriatic arthritis (PsA). In examining construct validity, we also addressed scores among subgroups with severe psoriasis, polyarticular disease, enthesitis and dactylitis and evaluated influences of sociodemographic factors and comorbidities (contextual factors) on these patient-reported outcomes (PROs). METHODS:Patients with PsA were enrolled in the Psoriatic Arthritis Research Consortium (PARC) between 2014-2016. PARC is a longitudinal observational cohort study conducted at four United States institutions. In this cross-sectional study, construct validity was assessed by examining Spearman's correlation coefficients for RAPID3 and PSAID with physician-reported disease activity measures and other PROs (e.g., Short Form 12 (SF12-PCS/-MCS), Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue). Contextual factors and disease subgroups were assessed in multivariable linear regression models with RAPID3 or PSAID12 as outcomes of interest and the hypothesized contextual factors as covariates. RESULTS: Among 401 patients enrolled in PARC, 347 completed RAPID3 or PSAID12. Of these, most were Caucasian females with a mean age of 51.74 (SD 14.02). RAPID3 and PSAID were highly correlated (r=0.90). These measures were also correlated with the SF12-PCS (r=-0.67) and FACIT-Fatigue (r=-0.77). Important contextual factors and disease subgroups included enthesitis, joint counts, education, insurance type, and depression. CONCLUSION: RAPID3 and PSAID12 have excellent construct validity in PsA and are strongly correlated despite differing items. Contextual factors (i.e., the presence of depression and obesity) should be considered when interpreting raw scores of the RAPID3 and PSAID12.
Authors: Fabiola Atzeni; Elisabetta Gerratana; Ignazio Francesco Masala; Sara Bongiovanni; Piercarlo Sarzi-Puttini; Javier Rodríguez-Carrio Journal: Front Med (Lausanne) Date: 2021-08-30
Authors: Louise Ward; Michael Oliffe; Barry Kane; Diana Chessman; Donna Meaney; Fiona Briggs; Kathryn Gibson; Les Barnsley; Daniel Sumpton Journal: Int J Rheum Dis Date: 2022-03-25 Impact factor: 2.558